A Trillion-Dollar "Gray Market" on the Path to Legalization
U.S. May Ease Restrictions on Peptides
Time：
2026-04-17 08:16
Author：
xieyijun
Pursuing innovation is the only path out.
Time：
2026-04-16 08:17
Author：
xieyijun
A Fresh M&A War Over RAS Inhibitors Is Set to Ignite
Time：
2026-04-15 08:14
Author：
xieyijun
Oral macrocyclic peptides are quietly taking off.
Is it a bubble, or a new starting point?
Time：
2026-04-14 08:13
Author：
xieyijun
Chinese innovative pharmaceutical companies' 'physical body going global'
Time：
2026-04-12 17:36
Author：
xieyijun
The Golden Waterway for Innovative Drugs Is Now Open
Behind Merck stand a host of Chinese pharmaceutical companies.
Time：
2026-04-10 19:31
Author：
xieyijun
In the Second Half of the ADC Era, What Cards Does China’s Innovative Drug Industry Hold?
China’s ADCs: Going Global Continues
Time：
2026-04-10 08:12
Author：
xieyijun
The Emergence of In Vivo CAR-Tumor: A Disruptor in Immune Cell Therapy
Interview with Dr. Zhou Guoqing, Inventor of In Vivo CAR-Tumor
Time：
2026-04-09 09:15
Author：
xieyijun
Recommended content
mRNA tumor vaccine "seller", entering a golden age
When a Biotech company that has been acquired achieves rare growth
AI、 Cold bench and puzzle, when will 'one person, one seedling' come to an end?
This road is long, but the threshold has already been crossed.
The "economic accounts" of immunology business development are being rewritten
After rejecting a $30 billion acquisition offer, a biotech company has emerged as a giant
determination for independence
联系我们
同写意
写意宣发
同写意Biotech
同写意微服务